Gabapentin Capsule
Product Images NDC 64380-869

9 FDA label images from Strides Pharma Science Limited · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 64380-869). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Strides Pharma Science Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Cockcroft And Gault Equation (979787f3 7230 4586 862f 5c05686b8a43 01)

Cockcroft And Gault Equation (979787f3 7230 4586 862f 5c05686b8a43 01)
A formula depicting creatinine clearance (CLCr) calculation based on age in years, weight in kilograms, serum creatinine in mg/dL, with an adjustment factor of 0.85 for female patients. This equation estimates renal function relevant to gabapentin dosing.*
FDA Label Image

Image (979787f3 7230 4586 862f 5c05686b8a43 02)

Image (979787f3 7230 4586 862f 5c05686b8a43 02)
Chemical structure of gabapentin, showing a cyclohexane ring with an amino group and a carboxymethyl group attached to the same carbon atom.*
FDA Label Image

Figure 1. Weekly Mean Pain Scores (observed Cases In Itt Population): Study 1 (979787f3 7230 4586 862f 5c05686b8a43 03)

Figure 1. Weekly Mean Pain Scores (observed Cases In Itt Population): Study 1 (979787f3 7230 4586 862f 5c05686b8a43 03)
A line graph showing mean pain score over 8 weeks comparing placebo and gabapentin 3600 mg/day. The x-axis represents weeks from baseline to week 8, and the y-axis shows mean pain scores from 0 to 10. The graph indicates a 4-week dose titration period followed by a 4-week fixed dose period, with gabapentin showing a progressive decrease in pain score compared to placebo.*
FDA Label Image

Figure 2. Weekly Mean Pain Scores (observed Cases In Itt Population): Study 2 (979787f3 7230 4586 862f 5c05686b8a43 04)

Figure 2. Weekly Mean Pain Scores (observed Cases In Itt Population): Study 2 (979787f3 7230 4586 862f 5c05686b8a43 04)
A line graph displaying mean pain scores over a 7-week period comparing placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day. The x-axis represents weeks, showing a 3-week dose titration period followed by a 4-week fixed dose period. The y-axis shows mean pain scores from 0 to 10, with Gabapentin groups showing a decline in pain score compared to placebo.*
FDA Label Image

Figure 3. Proportion Of Responders (patients With ≥ 50% Reduction In Pain Score) At Endpoint: Controlled Phn Studies (979787f3 7230 4586 862f 5c05686b8a43 05)

Figure 3. Proportion Of Responders (patients With ≥ 50% Reduction In Pain Score) At Endpoint: Controlled Phn Studies (979787f3 7230 4586 862f 5c05686b8a43 05)
A bar chart titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' comparing placebo (PBO) to gabapentin (GBP) at different doses across two studies. Study 1 shows 12% responders for placebo and 29% for GBP 3600 mg. Study 2 shows 14% responders for placebo, 32% for GBP 1800 mg, and 34% for GBP 2400 mg. Statistical significance is indicated for the gabapentin groups.*
FDA Label Image

Figure 4. Responder Rate In Patients Receiving Gabapentin Expressed As A Difference From Placebo By Dose And Study: Adjunctive Therapy Studies In Patients ≥ 12 Years Of Age With Partial Seizures (979787f3 7230 4586 862f 5c05686b8a43 06)

Figure 4. Responder Rate In Patients Receiving Gabapentin Expressed As A Difference From Placebo By Dose And Study: Adjunctive Therapy Studies In Patients ≥ 12 Years Of Age With Partial Seizures (979787f3 7230 4586 862f 5c05686b8a43 06)
A scatter plot comparing the difference (%) on the vertical axis against daily dose (mg) on the horizontal axis, including data points from three studies labeled 'Study a', 'Study b', and 'Study c'. Values range from about 7% to 18% difference across doses of 600 mg, 900 mg, 1200 mg, and 1800 mg.*
FDA Label Image

Gabapentin Capsules 100mg (100S)

Gabapentin Capsules 100mg (100S)
Label text panel for Gabapentin Capsules, USP 100 mg by Strides Pharma Science Limited. Includes usual dosage instructions, packaging storage requirements (child-resistant, 25°C with excursions 15°C to 30°C), contents per capsule (Gabapentin 100 mg), dispensing guidance for pharmacists, and container warnings. Lists manufacturer and distributor details plus space for batch information.*
FDA Label Image

Gabapentin Capsules 300mg (100S)

Gabapentin Capsules 300mg (100S)
Label for Gabapentin Capsules, USP 300 mg by Strides Pharma Science Limited, indicating a package of 100 capsules. The label includes storage instructions, child-resistant packaging notice, and a warning to keep medication out of reach of children. It also provides manufacturer and distributor information, a pharmacist medication guide link, and placeholders for batch details.*
FDA Label Image

Gabapentin Capsules 400mg (100S)

Gabapentin Capsules 400mg (100S)
Label for Gabapentin Capsules, USP 400 mg by Strides Pharma Inc. The label specifies the capsule strength as 400 mg, package count of 100 capsules, and indicates it is Rx only. It includes storage instructions, child-resistant packaging notice, and pharmacist dispensing information. The manufacturer is Strides Pharma Science Ltd., Puducherry, India, with distribution by Strides Pharma Inc., Bridgewater, NJ.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.